Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Mayo Clinic
Kivu Bioscience Inc.
AstraZeneca
STORM Therapeutics LTD
Eli Lilly and Company
Neonc Technologies, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Seagen Inc.
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Genentech, Inc.
Clasp Therapeutics, Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
DualityBio Inc.
MacroGenics
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
Innate Pharma
Elephas
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Tanabe Pharma America, Inc.
Therorna
West China Hospital
DualityBio Inc.
Volastra Therapeutics, Inc.
M.D. Anderson Cancer Center
LigaChem Biosciences, Inc.
Nurix Therapeutics, Inc.
Guardant Health, Inc.
Bicara Therapeutics
Yuhan Corporation
Totus Medicines
Precision Biologics, Inc
Cancer Research UK
Evopoint Biosciences Inc.
HRYZ Biotech Co.